The role of monototal in the primary diagnosis, prognosis and follow-up of patients with non-small cell lung cancer (NSCLC)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A9399" target="_blank" >RIV/00216208:11110/11:9399 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/11:10103150 RIV/00064165:_____/11:9399

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The role of monototal in the primary diagnosis, prognosis and follow-up of patients with non-small cell lung cancer (NSCLC)

Popis výsledku v původním jazyce

A new cytokeratin tumor marker, MonoTotal was studied in lung cancer, the most common cause of cancer mortality worldwide. In non-small cell lung cancer (NSCLC) patients MonoTotal serum levels and their relationship to the tumor stage, histological subtype, early relapse and cancer-related death were evaluated. Patients and Methods: MonoTotal serum levels were studied, using immunoradiometric assay in a group of 93 patients with newly diagnosed NSCLC undergoing radical surgery, and were compared to those with benign lung diseases. Results: A diagnostic power of MonoTotal in distinguishing patients with NSCLC from benign lung diseases was demonstrated. Higher levels of Mono Total were associated with advanced stages of squamous cell carcinoma and therewas a positive correlation of marker with tumor size. Marker levels showed significant relation to disease-free survival and overall survival. Conclusion: MonoTotal seems to be a potentially very interesting serum marker that, in conjunct

Název v anglickém jazyce

The role of monototal in the primary diagnosis, prognosis and follow-up of patients with non-small cell lung cancer (NSCLC)

Popis výsledku anglicky

A new cytokeratin tumor marker, MonoTotal was studied in lung cancer, the most common cause of cancer mortality worldwide. In non-small cell lung cancer (NSCLC) patients MonoTotal serum levels and their relationship to the tumor stage, histological subtype, early relapse and cancer-related death were evaluated. Patients and Methods: MonoTotal serum levels were studied, using immunoradiometric assay in a group of 93 patients with newly diagnosed NSCLC undergoing radical surgery, and were compared to those with benign lung diseases. Results: A diagnostic power of MonoTotal in distinguishing patients with NSCLC from benign lung diseases was demonstrated. Higher levels of Mono Total were associated with advanced stages of squamous cell carcinoma and therewas a positive correlation of marker with tumor size. Marker levels showed significant relation to disease-free survival and overall survival. Conclusion: MonoTotal seems to be a potentially very interesting serum marker that, in conjunct

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

31

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

3107-3112

Kód UT WoS článku

000293357700060

EID výsledku v databázi Scopus

—